清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

[Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].

生物仿制药 肝细胞癌 贝伐单抗 医学 经动脉栓塞 肿瘤科 内科学 放射科 栓塞 化疗
作者
Hao Yang,Jennifer T. Huang,Dan Hu,Baiyu Zhong,Jian Shen,Xiaoli Zhu
出处
期刊:PubMed [National Institutes of Health]
卷期号:64 (2): 134-141
标识
DOI:10.3760/cma.j.cn112138-20240805-00492
摘要

Objective: To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma (uHCC). Methods: The clinical data of 64 patients with unresectable HCC, who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023, were retrospectively analyzed. The patients were divided into a combination group (n=43, receiving TACE combined with sintilimab and bevacizumab biosimilar) and control group (n=21, receiving only sintilimab and bevacizumab biosimilar). Survival curves were drawn by Kaplan-Meier method, and the median overall survival (mOS) and median progression-free survival (mPFS) were compared between the two groups. According to the mRECIST criterion, the objective response rate (ORR) and disease control rate (DCR) were compared between the two groups. The occurrences of adverse events in both groups were recorded. Results: The mOS and mPFS in the combination group were 22.3 months and 12.4 months, respectively, which in the control group was 11.6 months and 6.4 months, respectively. The differences between the two groups were statistically significant (P=0.001 and P=0.002). The ORR and DCR in the combination group were 62.8% and 95.3% respectively, which were significantly higher than 19.0% and 57.1% respectively in the control group (all P<0.01). No statistically significant difference in the incidence of severe adverse events existed between the two groups (P=0.518). Conclusion: TACE combined with sintilimab and bevacizumab biosimilar has efficacy and safety than sintilimab and bevacizumab biosimilar alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
搜集达人的应助被科研通管家采纳,获得10
1秒前
1秒前
zilicai的应助被科研通管家采纳,获得10
1秒前
星辰大海的应助被科研通管家采纳,获得10
1秒前
2秒前
ding的应助被科研通管家采纳,获得10
2秒前
烂漫的诗蕊完成签到,获得积分10
2秒前
2秒前
physicalpicture完成签到,获得积分10
6秒前
广州小肥羊完成签到 ,获得积分10
33秒前
38秒前
高高的玉兰完成签到,获得积分10
41秒前
体贴的惜文完成签到,获得积分10
42秒前
49秒前
KalEl发布了新的文献求助10
49秒前
55秒前
irisxiong完成签到,获得积分10
56秒前
笔墨纸砚完成签到 ,获得积分10
1分钟前
务实的海豚完成签到,获得积分10
1分钟前
共享精神的应助被兰兰不懒采纳,获得10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
天很蓝完成签到,获得积分10
1分钟前
饱满飞绿完成签到,获得积分10
1分钟前
子凡完成签到 ,获得积分10
1分钟前
自由的冷玉完成签到,获得积分10
1分钟前
风息完成签到,获得积分10
1分钟前
1分钟前
会飞的鹦鹉完成签到,获得积分10
1分钟前
兰兰不懒发布了新的文献求助10
2分钟前
2分钟前
2分钟前
科研通AI65的应助被科研通管家采纳,获得10
2分钟前
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
SAY完成签到 ,获得积分10
2分钟前
fantasy的应助被shine采纳,获得10
2分钟前
激动的似狮完成签到,获得积分10
2分钟前
2分钟前
KalEl发布了新的文献求助10
2分钟前
chemlink完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577355
关于积分的说明 21852358
捐赠科研通 7788746
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482911